Angion Biomedica Corp. (NASDAQ:ANGN – Get Rating) shares rose 2% during trading on Monday . The stock traded as high as $1.06 and last traded at $1.00. Approximately 224,800 shares changed hands during mid-day trading, an increase of 159% from the average daily volume of 86,718 shares. The stock had previously closed at $0.98.
Angion Biomedica Price Performance
The firm has a fifty day moving average of $6.93 and a 200-day moving average of $7.22.
Institutional Trading of Angion Biomedica
Several hedge funds have recently added to or reduced their stakes in the business. Prudential Financial Inc. raised its stake in shares of Angion Biomedica by 102.4% in the 3rd quarter. Prudential Financial Inc. now owns 34,400 shares of the company’s stock worth $32,000 after buying an additional 17,400 shares in the last quarter. Millennium Management LLC purchased a new position in Angion Biomedica in the second quarter valued at about $209,000. Park West Asset Management LLC grew its stake in Angion Biomedica by 391.0% in the third quarter. Park West Asset Management LLC now owns 370,724 shares of the company’s stock valued at $341,000 after purchasing an additional 295,221 shares in the last quarter. CM Management LLC lifted its position in shares of Angion Biomedica by 9.3% in the first quarter. CM Management LLC now owns 800,000 shares of the company’s stock worth $464,000 after buying an additional 67,822 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Angion Biomedica by 17.1% in the first quarter. Renaissance Technologies LLC now owns 223,700 shares of the company’s stock worth $474,000 after buying an additional 32,600 shares during the last quarter. Institutional investors own 17.00% of the company’s stock.
About Angion Biomedica
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung.
Featured Articles
- Get a free copy of the StockNews.com research report on Angion Biomedica (ANGN)
- Trading Stocks: RSI and Why it’s Useful
- Why Mosaic’s Price Targets May Be Understated
- Amazon And The AI War: iRobot Acquisition In Focus
- What Does Logitech CEO’s Abrupt Departure Mean?
- Ulta Beauty Stock Value is More Than Skin Deep
Receive News & Ratings for Angion Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Angion Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.
